Results 101 to 110 of about 461 (138)

Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives. [PDF]

J Clin Med
Alfarano M, Ciccarelli F, Marchionni G, Ballatore F, Costantino J, Lattanzio A, Pecci G, Stavagna S, Iannelli L, Galardo G, Lavalle C, Miraldi F, Vizza CD, Chimenti C.   +13 more
europepmc   +1 more source

Myosin inhibitors for treatment of hypertrophic cardiomyopathy. [PDF]

Cochrane Database Syst Rev
Quill S, Amin AS, Asselbergs FW, Bezzina C, Elliott PM, van der Velden J, Schmidt AF.   +6 more
europepmc   +1 more source

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology, 2023
Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients.This study aims to evaluate the safety and efficacy of aficamten in patients with oHCM ...
Pablo García-Pavía, Albree Tower-Rader, Caroline Coats   +2 more
exaly   +5 more sources

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Background: A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients’ health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been comprehensively described. Objectives: This study sought to determine the effect of aficamten
Michael E Nassif, Lisa Meng, Amy Wohltman   +2 more
exaly   +4 more sources

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and stroke. Aficamten is a next-in-class cardiac myosin inhibitor that reduces outflow tract obstruction by
Lisa Meng, Amy Wohltman, Ahmad Masri
exaly   +3 more sources

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology
Background: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in ...
Michael E Nassif, Lisa Meng, Amy Wohltman   +2 more
exaly   +2 more sources

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure
Michael E Nassif, Albree Tower-Rader, Michael A Fifer   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Echocardiographic Changes With Aficamten

Journal of the American College of Cardiology
Milind Y Desai
exaly   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Srihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources